Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma

American Journal of Hematology

Volumn 91, Issue 6, 2016, Pages 571-574

  Lust, John A ^a   Lacy, Martha Q ^a   Zeldenrust, Steven R ^a   Witzig, Thomas E ^a   Moon Tasson, Laurie L ^a   Dinarello, Charles A ^b   Donovan, Kathleen A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; M-PROTEINS (MYELOMA);

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CATARACT; CLINICAL ARTICLE; COLON PERFORATION; FEMALE; HEART INFARCTION; HUMAN; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG EFFECTS; FOLLOW UP; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PROCEDURES; SURVIVAL ANALYSIS;

C-REACTIVE PROTEIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SURVIVAL ANALYSIS;

EID: 84963893691     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24352     Document Type: Article

References (27)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2007; 21:1093-1113.
2. International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-757.
3. Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016; 91:90-100.
4. Greipp PR. Smoldering, asymptomatic stage 1, and indolent myeloma. Curr Treat Options Oncol 2000; 1:119-126.
5. Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013; 122:4172-4181.
6. Mateos M-V, Hernandez M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013; 369:438-447.
7. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84:114-122.
8. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-85.
9. Schwab G, Siegall CB, Aarden LA, et al. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77:587-593.
10. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73:517-526.
11. Portier M, Rajzbaum G, Zhang XG, et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21:1759-1762.
12. Donovan KA, Lacy MQ, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 1998; 12:593-600.
13. Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93:300-305.
14. Xiong Y, Donovan KA, Kline MP, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006; 26:83-95.
15. Berrahmoune H, Herbeth B, Lamont JV, et al. Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. Clin Chem Lab Med 2007; 45:1339-1346.
16. Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62:969-977.
17. Witzig TE, Gertz MA, Lust JA, et al. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: When is the optimal time for stem cell harvest? Leuk Lymphoma 1995; 19:417-422.
18. Kyle RA, Remstein ED, Therneau TM, et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. N Engl J Med 2007; 356:2582-2590.
19. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010; 29:317-329.
20. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147.
21. Morice WG, Hanson CA, Kumar S, et al. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007; 21:2043-2046.
22. Dinarello CA. Targeting the pathogenic role of interleukin 1 in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 2009; 84:105-107.
23. Miwa H, Kanno H, Munakata S, et al. Induction of chromosomal aberrations and growth-transformation of lymphoblastoid cell lines by inhibition of reactive oxygen species-induced apoptosis with interleukin-6. Lab Invest 2000; 80:725-734.
24. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Huntington) 2002; 16:217-226. 229; discussion 230-212.
25. Kiraly O, Gong G, Olipitz W, et al. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genet 2015; 11:e1004901
26. Moline JM, Herbert R, Crowley L, et al. Multiple myeloma in World Trade Center responders: a case series. J Occup Environ Med 2009; 51:896-902.
27. Li J, Cone JE, Kahn AR, et al. Association between World Trade Center exposure and excess cancer risk. JAMA 2012; 308:2479-2488.